Gadobenate dimeglumine has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Gadobenate dimeglumine is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

There are no data on the excretion of gadobenate dimeglumine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, nursing should be discontinued prior to administration of gadobenate dimeglumine and should not be restarted until at least 24 hours after administration.

See references